Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SEL-110
- Development stage
- Unknown
- Lead developer
- Cartesian Therapeutics
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
SEL-110 is a proprietary immunomodulatory therapeutic developed to mitigate immune responses and induce antigen-specific immune tolerance. It consists of tolerogenic nanoparticles containing sirolimus (rapamycin) and is designed to prevent the formation of anti-drug antibodies (ADAs) against biologic drugs when co-administered. The primary mechanism involves inhibition of the mTOR protein pathway and stimulation of methylmalonyl CoA mutase. SEL-110 has been investigated primarily for use in combination therapies for gout refractory to standard treatments (notably as part of the combination product SEL-212 with pegsiticase/SEL-037), where it helps sustain uricase activity by reducing ADA formation. The drug has reached Phase III clinical trials for gout but has not advanced in other indications such as methylmalonic acidaemia or immunological disorders[1][3][5][7].
- Other names
- ImmTORSVP RapamycinSVP-R
02
Targets
Mechanistic target of rapamycin complex 1MMUT (Methylmalonyl-coenzyme A mutase)
Beyond the preview
Go deeper on SEL-110.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SEL-110.